Nurix, Inc. announced the appointment of Arthur T. Sands, M.D., Ph.D., as chief executive officer. Dr. Sands succeeds interim chief executive officer Mark A. Goldsmith, M.D., Ph.D., a partner at Third Rock Ventures, who will continue service to the company as chairman of its board of directors. In conjunction with this appointment, the company also named Pierre Beaurang, Ph.D., vice president, business and corporate development.

Prior to joining the company, Dr. Sands co-founded Lexicon Pharmaceuticals and served as president, chief executive officer and a director since 1995. Dr. Sands serves as adjunct professor in the Department of Human and Molecular Genetics at Baylor College of Medicine. Dr. Beaurang brings to the company nearly 15 years of business and operational experience in the biotechnology industry.

Prior to joining the company, Dr. Beaurang was part of the founding team of Five Prime Therapeutics, contributing to the conceptualization, creation and implementation of the company plan and serving in multiple operational and business development roles of increasing responsibility through his appointment as executive director of business development.